Ensign Peak Advisors Inc Has $26.11 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Ensign Peak Advisors Inc raised its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 21.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 378,060 shares of the biopharmaceutical company's stock after acquiring an additional 67,412 shares during the period. Ensign Peak Advisors Inc owned approximately 0.20% of Incyte worth $26,113,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in INCY. Deutsche Bank AG increased its position in shares of Incyte by 22.6% during the 4th quarter. Deutsche Bank AG now owns 1,176,137 shares of the biopharmaceutical company's stock valued at $81,236,000 after purchasing an additional 217,109 shares during the period. Colonial Trust Co SC increased its position in shares of Incyte by 41.7% during the 4th quarter. Colonial Trust Co SC now owns 1,481 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 436 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Incyte by 270.4% during the 4th quarter. Cubist Systematic Strategies LLC now owns 263,019 shares of the biopharmaceutical company's stock valued at $18,167,000 after purchasing an additional 192,004 shares during the period. Cetera Investment Advisers increased its position in shares of Incyte by 10.8% during the 4th quarter. Cetera Investment Advisers now owns 13,288 shares of the biopharmaceutical company's stock valued at $918,000 after purchasing an additional 1,294 shares during the period. Finally, Brevan Howard Capital Management LP increased its position in shares of Incyte by 43.9% during the 4th quarter. Brevan Howard Capital Management LP now owns 52,953 shares of the biopharmaceutical company's stock valued at $3,657,000 after purchasing an additional 16,164 shares during the period. Institutional investors own 96.97% of the company's stock.

Analysts Set New Price Targets

INCY has been the topic of a number of recent research reports. Wells Fargo & Company lifted their target price on Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Royal Bank of Canada boosted their price target on Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a research report on Wednesday, April 30th. StockNews.com upgraded Incyte from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 30th. Stifel Nicolaus boosted their price target on Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. lowered their price target on Incyte from $70.00 to $68.00 and set a "neutral" rating on the stock in a research note on Monday, April 21st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Incyte currently has a consensus rating of "Hold" and an average target price of $73.53.

Incyte Price Performance

Shares of INCY traded up $0.35 on Wednesday, hitting $61.16. The company's stock had a trading volume of 2,143,865 shares, compared to its average volume of 2,335,794. The company has a market capitalization of $11.84 billion, a PE ratio of 226.53, a PEG ratio of 0.41 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. Incyte Co. has a fifty-two week low of $53.56 and a fifty-two week high of $83.95. The company has a 50 day moving average price of $60.95 and a 200 day moving average price of $68.61.

Incyte (NASDAQ:INCY - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, topping the consensus estimate of $1.01 by $0.15. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $996.17 million. Incyte had a return on equity of 0.05% and a net margin of 0.77%. Incyte's revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS. On average, research analysts anticipate that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Insider Activity at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,809,101.52. This represents a 2.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the transaction, the executive vice president now owns 33,567 shares of the company's stock, valued at approximately $2,272,150.23. This trade represents a 37.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,475 shares of company stock worth $2,424,751 in the last quarter. Corporate insiders own 17.80% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.